business loans are published in the quarterly E.2 statistical release, *Survey of Terms of Business Lending,* and aggregate estimates for farm loans are published in the E.15 statistical release, *Agricultural Finance Databook.*

Legal authorization and confidentiality: The Board's Legal Division has determined that these surveys are authorized by section 11(a)(2) of the Federal Reserve Act (12 U.S.C. 248(a)(2)) which authorizes the Board to require any depository institution to make such reports of its assets and liabilities as the Board may determine to be necessary or desirable to enable the Board to discharge its responsibility to monitor and control monetary and credit aggregates. The reports are voluntary. Individual responses reported on the FR 2028A, FR 2028B, FR 2028D, and FR 2028S are regarded as confidential under the Freedom of Information Act (5 U.S.C. 552(b)(4)).

Current actions: On April 21, 2017, the Board published a notice in the **Federal Register** (82 FR 18759) requesting public comment for 60 days on the extension, with revision, of the FR 2028. The Federal Reserve proposed to (1) discontinue the FR 2028A, (2) create a new Small Business Lending Survey (FR 2028D) that would provide focused and enhanced information on small business lending including rates, terms, credit availability, and reasons for their changes (in contrast to the individual loan data collected on the FR 2028A, the FR 2028D would collect quarterly average quantitative data on terms of small business loans and qualitative information on changes and the reasons for changes in the terms of lending), and (3) rename the STL the Survey of Small Business and Farm Lending (SSBFL) to more accurately describe the data collection. No changes were proposed to the FR 2028B and FR 2028S. The comment period for this notice expired on June 20, 2017. The Board did not receive any comments. The revisions will be implemented as proposed.

Board of Governors of the Federal Reserve System, July 5, 2017.

Ann E. Misback,

Secretary of the Board.

[FR Doc. 2017–14401 Filed 7–7–17; 8:45 am]

BILLING CODE 6210–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Sunshine Act Meeting: Advisory Council for the Elimination of Tuberculosis Meeting (ACET)

TIME AND DATE: 10:00 a.m.–3:30 p.m., EDT, August 22, 2017

PLACE: Web conference. Toll free number 1–877–927–1433, Participant Code: 12016435, To join the meeting: *https://adobeconnect.cdc.gov/r5p8l2tytpq/.*

STATUS: In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention announces the meeting of the ACET. This meeting is open to the public. The meeting room accommodates 100 ports. Persons who desire to make an oral statement, may request it at the time of the public comment period on August 22, 2017 at 3:20p.m. EDT. Public participation and ability to comment will be limited to space and time as it permits.

MATTERS TO BE CONSIDERED: This council advises and makes recommendations to the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the elimination of tuberculosis (TB). Specifically, the Council makes recommendations regarding policies, strategies, objectives, and priorities; addresses the development and application of new technologies; and reviews the extent to which progress has been made toward eliminating tuberculosis. Agenda items include the following topics: (1) Update on making latent tuberculosis infection (LTBI) reportable from the Council of State and Territorial Epidemiologists (CSTE) meeting; (2) Update data on LTBI testing and treatment from Aggregate Reports for Tuberculosis Program Evaluation (ARPE); (3) Update on CDC's efforts to transition to whole-genome sequencing; (4) Updates from Workgroups; and (5) other tuberculosis-related issues. Agenda items are subject to change as priorities dictate.

CONTACT PERSON FOR MORE INFORMATION: Margie Scott-Cseh, CDC, 1600 Clifton Road NE., M/S E–07, Atlanta, Georgia 30333, telephone (404) 639–8317; Email: *zkr7@cdc.gov.*

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Claudette Grant,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 2017–14516 Filed 7–6–17; 4:15 pm]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Sunshine Act Meeting: Advisory Board on Radiation and Worker Health (ABRWH or Advisory Board), National Institute for Occupational Safety and Health (NIOSH)

TIME/S/ AND DATE/S/:

8:15 a.m.–5:30 p.m., Mountain Time, August 23, 2017

8:15 a.m.–4:30 p.m., Mountain Time, August 24, 2017

PUBLIC COMMENT TIMES AND DATES: 5:30 p.m.–6:30 p.m., Mountain Time, August 23, 2017.

PLACE: Courtyard Marriott, 3347 Cerrillos Road, Santa Fe, New Mexico 87507; Phone: (505) 473–2800 Fax: (505) 473–5128.

STATUS: In accordance with section 10(a) (2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting of the aforementioned committee. This meeting is Open to the public, limited only by the space available. The meeting space accommodates approximately 100 people. Audio Conference Call via FTS Conferencing. The USA toll-free, dial-in number is 1–866–659–0537 with a pass code of 9933701. *Skype Meeting Connection: https://webconf.cdc.gov/zab6/yzdq02pl?sl=1*

MATTERS TO BE CONSIDERED: The Advisory Board was established under the Energy Employees Occupational Illness Compensation Program Act of 2000 to advise the President on a variety of policy and technical functions required to implement and effectively manage the new compensation program. Key functions of the Advisory Board include providing advice on the development of probability of causation guidelines which have been promulgated by the Department of Health and Human Services (HHS) as a final rule, advice on methods of dose reconstruction which have also been